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Background: What do patients expect from a treatment? A patient-centred approach to treatment is becoming
necessary given the choices for invasive treatments for Parkinson’s disease. Patient’s perceptions of severity and
expectations from complex therapies have not been studied. We describe the rationale and concept of developing
a Patient-Reported Outcome (PRO) tool to assess perceptions of symptom severity and expectations of therapy. We
report preliminary findings from use of the tool, association with clinical factors, and illustrate the potential use in
individual patients awaiting therapy.
Methods: Patient symptoms were grouped into four domains, with 8 motor, 7 non-motor, 7 psychological and 4
social questions. For each question, symptom severity was rated on a Likert scale scoring from 0 (no problem) to 7
(perceived as a severe problem). Similarly, the expectation for each symptom to change after therapy was rated on
a Likert scale: score −3 (expected to be very much worse) to + 3 (expected to be very much improved).
Results: 22 consecutive patients, routinely planned to receive one of Deep Brain Stimulation/Intrajejunal Levodopa
Infusion/Apomorphine Infusion therapies, were recruited: 13 male, mean (+/−sd) age: 65.6 (+/−9.5) years, mean (+/−sd)
disease duration: 14.3 (+/−5.7) years. Subjective severity scores are reported as mean (+/−sd) / maximum possible
score: (i) motor 23.5 (+/−7.5) / 56, (ii) non-motor 15.5 (+/−5.6) / 49, (iii) cognitive - psychological 12.4 (+/−5.8) / 49,
(iv) social 9.3 (+/−4.1) / 28. Expectation of change (improvement) scores are reported as mean (+/−sd) / maximum
possible score of: (i) motor 14.0 (+/−5.6) / 24, (ii) non-motor 8.5 (+/−4.1) / 21, (iii) cognitive - psychological 7.4 (+/−4.4)/ 21,
and (iv) social 5.5 (+/−2.8) / 12. For each domain, Spearman correlation coefficient showed significant associations
between severity and expectation within-domain.
Conclusion: This tool (PRO-APD) provides a description of perceived problem severity and expectation of
treatments encompassing a holistic patient-driven view of care. PD patients about to receive complex therapy have
moderately high perception of symptom load in multiple domains, and expect substantial improvements in multiple
domains. These preliminary findings may be useful in documenting multi-domain symptoms, as well as counseling
patients to help them reach realistic expectations and reduce potential dissatisfaction following therapy.* Correspondence: preddy@nhs.net
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Parkinson’s disease (PD) is a progressive neurodegenerative
disorder affecting a wide range of motor and non-motor
functions, and leading to marked disability in its later
stages. At a population level, subjective health status
(quality of life) is associated with both motor and non-
motor symptoms (NMS) [1-3]. However, for individual
patients, the perceived significance of different motor
and non-motor symptoms is likely to be influenced by the
extent to which they interfere with particular aspects of
their life, some of which will be specific to the individual
(e.g. in relation to occupation and recreation).
Once a treatment is suggested, the question of “how do
we know if that treatment works?” remains a complex one.
The ability of treatment to manage individually important
symptoms may influence a patient’s preferences for and
expectations of treatment, for example a watchmaker
affected by tremor. Particularly pertinence applies when
using complex, invasive, expensive therapies, such as deep
brain stimulation (DBS), Intrajejunal Levodopa Infusion
(IJL) and subcutaneous Apomorphine (Apo) infusions,
because these can offer marked benefits for some but not
all symptoms of PD, but require high levels of expertise,
high costs and demand significant time requirements from
health care providers [4].
Understanding the individual patient’s perceptions of
the importance of specific symptoms and expectations of
treatment is important clinically for a number of reasons.
Firstly, where a choice of treatments is available it may be
possible to choose or tailor the treatment better to suit the
patient’s requirements. For example, the optimal dose of
dopaminergic stimulation or DBS parameters for motor
control may not necessarily be optimal for cognition or
other NMS. Secondly, it will help patients and those
treating them make better-informed decisions amongst
treatment options where those treatments vary in how
well they deal with specific problems. Thirdly, identifying
possibly unrealistic expectations may be useful in preparing
patients for the most likely clinical outcome and minimize
adverse emotional reactions following treatment. Ultim-
ately, the patient’s perception of the ability of a treatment
to improve the personally relevant (patient – centred)
aspects of their condition is the primary indicator of that
treatment’s success.
Patient-Reported Outcomes (PRO) were defined nearly
a decade ago by the US Food and Drug Administration
(FDA) as “a patient’s report of a health condition and its
treatment” [5]. PRO are subjective assessments by the
patient of any aspect of health, e.g. symptoms, functional
status, psychological well-being, quality of life, preferences,
perceptions, and satisfaction with care [6]. Although there
are PRO scales (PDQ-8 and PDQ-39) used in Parkinson’s
disease, none to date capture patient perception and ex-
pectation from advanced treatment. One published studyhas explored patient perceptions and expectations to treat-
ment in PD, focusing only on the oral therapies but not the
advanced therapies in PD [7]. The present study sought to
assess patient perceptions of the severity and importance of
a range of symptoms and their personal impact, and their
expectation of improvement from the proposed therapy
for those symptoms. This preliminary pilot work assessed
the practicality of application of such a tool. Secondly we
wished to investigate correlations between symptom sever-
ity and expectation of change before therapy, as this has
not previously been explored for these therapies in PD.
Methods
The study was approved by the Regional ethics committee
of South East London: ref number: 10/H0808/46. The
funding source was a grant from King’s Health Partners,
obtained through open competition.
A local PRO scale was designed and titled provisionally
the Patient Reported Outcomes in Advanced Parkinson’s
disease (PRO-APD). The scale was designed taking into
consideration our experience with motor, non-motor, so-
cial and quality of life issues in Parkinson’s disease. The
questions were designed to encompass the spectrum of
problems/issues encountered by Parkinson’s disease patients.
We have a large local and regional clinic at our hospital
and the central themes of the questions was based on our
clinical impression, coupled with currently available con-
temporary views from the literature. In addition, a group
of patients was consulted with regards to the content and
individual questions before the pilot version of the scale
reported here was finalized. There were 8 motor, 7 non-
motor, 7 cognitive/psychological and 4 social questions,
giving a total of 26 questions (Appendix 1).
Within each domain, the individual symptom severity
was first rated by the patient on a visual Likert scale from
0 (“I do not have the problem”) to 7 (“I have a very severe
problem”). Next, expectations of therapy for each item
were rated on a second Likert scale. A bipolar scale was
used with 7 points from −3 (expected to be very much
worse) to +3 (expected to be very much improved), with
0 as expected to show no change post-therapy. The
scale was administered on paper to the participants with
the investigator present to help explain and answer any
questions.
Additionally, participants were assessed on a range of
other measures, the new Unified Parkinson’s Disease Rating
Scale (MDS-UPDRS) [8], Non-motor Symptoms Scale
(NMSS) [9], Parkinson’s Disease Questionnaire (8-item)
(PDQ-8) [10], Hospital Anxiety and Depression Scale
(HADS) [11] and Adenbrooke’s Cognitive Examination
Scale (Revised) (ACE-R) [12]. These scales are widely used
and validated for use in PD for their selected symptoms.
Participants with PD were included in the study if they
had already been selected to receive treatment with one
Table 1 Patient demographics, motor and non-motor
severity, quality of life, mood and cognition (N = 22)
Variable Mean (SD) Range
Age (years) 65.6 (9.5) 49 – 80
Duration of disease (years) 14.3 (5.7) 5 – 23
MDS-UPDRS-3 51.7 (15.8) 15 – 83
MDS-UPDRS-4 8.6 (6.4) 0 – 20
NMSS total 74.9 (28.9) 39 – 140
PDQ-8 total 37.3 (16.3) 12.5 – 65.6
HADS total 16.3 (6.6) 5 – 28
ACE-R total 90.1 (7.6) 73 – 100
Abbreviations: (MDS-UPDRS Revised Unified Parkinson’s Disease Rating Scale,
NMSS Non-Motor Symptoms Scale, PDQ-8 Parkinson’s disease quality of life
scale, HADS Hospital Anxiety and Depression Scale, ACE-R Addenbrooke’s
Cognitive Examination -Revised).
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routine care, at hospital-based clinical neurology settings at
King’s College Hospital NHS Foundation Trust, London
UK. Separate informed consent was obtained for entry into
the PRO-APD study. The PRO-APD severity and expect-
ation scales were applied following the clinical decision to
proceed but before the delivery of that therapy. In our
institution, this waiting time can range from 6 weeks to 6
months.
Data analysis and statistics
For each patient, items within each domain were summed
to give a domain score. The maximum possible scores for
severity domains were: motor 56, non-motor 49, psycho-
logical, 49, social 28. A total score was also calculated to
quantify the patient’s overall perceptions of their PD-related
problems. Whole group domain and total means were then
calculated.
For the expectation components, the ranges of possible
scores for change were motor −24 to +24, non-motor −21
to +21, cognitive/psychological −21 to +21, social −12
to +12. Negative values indicated that a patient was expect-
ing a worsening of symptoms after therapy. In practice, no
patient expected worsening on any problem. All individual
expectation scores and domain scores therefore indicated
either anticipations of no change or improvement. For each
patient, the scores for expectations of improvement from
each question in a domain were summed to give domain
scores of expectations of improvement. Whole group
domain and total means were then calculated. We also
calculated an overall mean total expectation score for
improvement, combining all domains.
Because of the different numbers of items in each do-
main, standardized scores were also calculated expressed
as a percentage of the maximum score possible for each
domain, for both severity and expectation.
Finally, we investigated total and domain-specific associa-
tions between severity and expectation. The Shapiro-Wilk
W-test showed that data of interest/variables were compat-
ible with a normal distribution. To assess associations, the
Spearman rank correlation coefficient was used due to the
small sample size. Correction for multiple comparisons was
not carried out, as this was a pilot exploratory study.
Results
A total of 22 consecutive patients were recruited for the
study (8 patients for STN DBS, 11 patients selected for
Apo, 3 patients for IJL) of which 13 were male and 9
female. The demographics are shown in Table 1. Table 2
shows the mean scores for each domain for severity and
for expectation, along with total scores. Severity scores for
the motor domain were rated highest and cognitive/
psychological the lowest. The expectations from therapy
showed the same pattern across the sample.Within domains, significant associations were found
between perceived severity and expectations for therapy in
each domain, with higher severity associated with higher
expected improvement (Table 2). Although significantly
associated in the group as a whole, there was evidence of
variability at the individual level between ratings of severity
and expectation. The scatterplots for each domain are
shown in Figures 1A-D. Two illustrative patients (‘X’ and
‘Y’) both scheduled for subcutaneous apomorphine infusion
are indicated, on the plots. Despite showing comparable
levels of perceived severity in most of the problem
domain, patients X and Y show very different expected
outcomes within three of the four domains. Schematic
views of profile scores across each of the PRO-APD
items are shown in Figure 2 (severity) and Figure 3
(expectation). To illustrate this further the following brief
cases vignettes are provided:
Patient X: 55 year old male, with a 9 year history of PD,
receiving treatment with ropinirole 24 mg, and levodopa/
carbidopa (100 mg/25 mg) 6 per day. His off-state MDS-
UPDRS-3 score was 83. There was no evidence of cognitive
impairment (ACE-R = 100) and only moderate levels of de-
pression/ anxiety (HADS total 12). His perceived severity
ratings indicated high levels of motor symptomatology. He
reported a range of marked non-motor problems including
sleep disturbance, bladder problems, pain and fatigue.
Cognitive and mood complaints were mild, but significant
impulsive behavior reported. Apart from self-care, aspects
of occupation and social function were subjectively mark-
edly affected. The patient expected the majority of the
problem reported across all domains rated to be ‘very
much improved’ by advanced treatment.
Patient Y: 56 year old male with a 13 year history of PD,
receiving treatment with rotigotine 16 mg, levodopa/
carbidopa (100 mg/25 mg) 18 per day, and levodopa/carbi-
dopa controlled release (200 mg/50 mg) at night. His off-
state MDS-UPDRS-3 score was 60. There was evidence of
Table 2 Domain and total PRO-APD scores of problem severity and expectation of change (N = 22)





Motor severity (max 56) 23.5 (7.5) 5 – 36 43.4% (13.9) 0.79 <0.001
Motor expectation of improvement (max 24) 14.0 (5.6) 1 – 21 58.3% (22.9)
NMS severity (max 49) 15.5 (5.6) 6 – 31 31.5% (11.2) 0.72 <0.001
NMS expectation of improvement (max 21) 8.5 (4.1) 2 – 16 40.3% (19.1)
Cognitive/psychological severity (max49). 12.4 (5.8) 0 – 24 25.2% (11.1) 0.68 <0.001
Cognitive/psychological expectation of
improvement (max 21)
7.4 (4.4) 0 – 16 35.3% (20.8)
Social severity (max 28) 9.3 (4.1) 3 – 16 33.1% (14.6) 0.62 0.002
Social expectation of improvement (max 12) 5.5 (2.8) 0 – 9 45.8% (23.1)
Total severity (max 182) 60.5 (16.7) 31 – 105 33.3% (9.4) 0.70 <0.001
Total expectation of improvement (max 78) 35.5 (14.1) 12 – 59 45.3% (17.6)
NMS = non-motor symptoms, SD = standard deviation.
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cant depression/anxiety (HADS total = 18). He reported
significant motor symptoms including problems with swal-
lowing and balance, plus fatigue, cognitive difficulties, and
depression. With the exception of impact on socializing,
however, his PD was not felt to have significant impact on
other activities. Despite the range and severity of problems
reported, he had only moderate expectations for the impact
on treatment on the motor and non-motor symptoms,
with no expectation of change for the cognitive or mood
problems.
Across domains, the perceived severities of the motor
problems were associated with the severity of non-motor
problems (r = 0.66, p < 0.001) and social problems (r = 0.44,
p < 0.05) but not the cognitive/psychological problems
(r = 0.16, p > 0.05). No association was found between
any of the other pairs of domains. For the expectation
scores, associations were higher for all domain pairs
(motor:non-motor, r = 0.72 , p < 0.001; motor:cognitive/
psychological, r = 0.51, p < 0.05; motor:social, r = 0.65,
p = 0.001; non-motor:cognitive/psychological, r = 0.44,
p < 0.05; non-motor:social, r = 0.63, p < 0.01; cognitive/
psychological:social, r = 0.59, p < 0.01).
The detailed associations between the perceived severity
and expectation domain scores and total scores, with a
range of clinical measures (UPDRS-III total score, NMSS
totals score, ACE-R total score and HADS total score)
are given in Table 3. Clinician rated motor severity was
moderately associated with patient perceptions of motor
problems but not with any other domain. Total NMSS
score was associated with all domains, most strongly with
the perceived severity of cognitive and psychological prob-
lems. The level of depression and anxiety as measured by
the HADS was strongly associated with perceived severity
of cognitive and psychological problems, with cognition
function as measured objectively by the ACE-R being
unrelated to any of the perceived severity scores. Forexpectation scores, UPDRS-III and NMSS were moderately
associated with expected motor change. NMSS, HADS and
ACE-R were all associated with greater expectation in the
cognitive and psychological domain, with worse NMSS,
greater depression/anxiety and better cognition associated
with greater expected improvement.
Discussion
The aim of this pilot study was to design a multidimen-
sional PRO assessment tool for PD patients scheduled
for an invasive therapy, and then to assess its practicality
in application and potential clinical utility at both group
and individual level. The measure is novel in combining
subjective perceptions of symptom difficulty with expecta-
tions of treatment outcome. Despite the small numbers
of patients assessed, we have shown that such a scale
can be pragmatic to use, even in a complex multimodal
disease, such as PD, and that it is able to provide clinically
meaningful information to supplement routine clinical as-
sessment. This approach allowed us to determine for each
individual a map of the patient’s perceptions of their dis-
ease and their expectation from treatment, and offer the
potential to help manage patients in preparing them for
therapy.
Traditionally, the measurement of improvement of par-
kinsonism by therapy has been by measuring motor signs
and broad measures of outcome, such as health-related
quality of life [13,14], The multiplicity of symptoms in PD
means that motor scores are not sufficient to describe
overall quality of life [3,9,15]. The impact of therapies on
the other aspects of PD is generally less well understood
and has been explored less than motor state [15-17]. This
is in line with data from others and our group that sug-
gests that standard PD severity scales are an insufficient
measure of disease burden. Indeed, the “gold standard”
Unified Parkinson’s Disease Rating Scale (UPDRS) has
been modified to the “new UPDRS” (MDS-UPDRS) for
Figure 1 Scatterplots showing relation between perceived severity and expected improvement for each of the 4 domains (solid line
represents the regression line and the dotted line the 95% confidence interval. Arrows indicate case examples X and Y). For the motor,
non-motor and cognitive/psychological domains, the severities in patients X and Y are comparable but expectations differ.
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standard scales, patients may describe being unhappy after
DBS [16,18]. Conversely, patients may be very satisfied
despite modest clinical gain. From our department, we
have noted a patient whose main desire for treatment of
her PD was the ability to “sit still and sew” [19]. Her degree
of satisfaction following DBS (“very pleased”) was notmatched by the minor improvement (< 10%) in the UPDRS
score. It is debatable which outcome measure was the more
clinically relevant. Further, the assessment of “success” from
a therapy can become more complex if one were to extend
analyses to include a more “complete” assessment of stage
of life, which would include social dynamics including
relationships/marriage [20]. Measuring treatment effects on
Figure 2 Profiles of perceived severity for illustrative cases X and Y (gaps indicate zero ratings), showing broadly similar severities
across individual symptom profiles.
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ability to move), is insufficient to determine if a therapy is
multi-dimensionally beneficial for a patient, cohort or
population, unless it is known that it is that symptom
(or set of symptoms) which is personally significant to
the patient. For example, we have observed that despite
“successful” DBS as determined by the patient, neurologist,
neuropsychologist, neuropsychiatrist and family practi-
tioner, a carer remained unhappy because the partner
had “changed”, no longer needing such intensive support
from the carer, leading to a mutually acceptable marriage
breakdown. In this complex circumstance, should the treat-
ment be considered “successful”? Should it be offered to
similar patients?
The PRO concept informing the present study is a move
away from assessments based on the clinical aim of “fix-
ing” the symptom/sign, and towards selecting treatments
that are best able to address a patient’s priorities across
the range of PD-related problems and their impact. The
concept is powerful and yet pragmatic, and is in line withtrends that encourage patient inclusion in treatment deci-
sions. This is a simple means of assessing the results of se-
verity and expectation for individuals and its meaning to
the patient [6]. Utilization of any PRO does not move
away from the need to use standard severity scales, nor
generic or specific quality of life scales. However, they can
help clinicians and researchers, jointly with the patient, to
understand better the impact of symptoms and proposed
treatments (rather than the physiological effect of treat-
ment on the sign). PRO-APD draws on three decades of
experience in the assessment of other chronic multifactor-
ial disorders (e.g. dementia [21], schizophrenia [22] and
neurorehabilitation [23]). Most importantly, there is now
guidance from both the FDA and European Medicines
Agency for the use of PRO measures in drug development
[24] and so one expects to see their increasing use over
the next generation of treatments.
As a first step, we report here the preliminary use in
assessing severity and expectation in a common disease,
even if it is as complex as PD. A further study is required
Figure 3 Profiles of expectations of improvement ratings for illustrative cases X and Y (gaps indicate zero ratings) showing clearly
different profiles of expectation following treatment.
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for assessment of objective and subjective outcomes after
therapy to determine whether “expected outcome” is
matched to “measured outcome”, and if not what the
impact of the discrepancy might be. With further extrapo-
lation, the measure should be equally applicable to other
adult or paediatric chronic movement disorders, like es-
sential tremor and dystonia with adjustment where neces-
sary of the problems assessed.
Unless a PRO is intended as a surrogate for traditional
conventional measures (e.g. self-report version of a clinical
scale for use in surveys), strong association are not ne-
cessarily expected or even necessary. In the present
case, patients were asked to assess the severity of the
PD-related problems and expectations of change. Given
the difference in the various scales, item content and
methods of assessment, we would expect only moderate
associations between self-rated problem domain severity
and standard scales. This was observed for motor prob-
lems (with MDS-UPDRS part 3, shown in Table 3), NMSproblems (with NMSS, shown in Table 3) and psycho-
logical and cognitive problems with (HADS but not
ACE-R, shown in Table 3). This latter result suggests that
the Cognitive/Psychological domain may be more sensi-
tive to measuring mood problems in the present sample.
Subjective ratings of cognition have also typically been
found to be unrelated to objective measurements across
the age span [25].
At a group level, there was evidence for a robust asso-
ciation between the perceived severity of the different
problems domains and the expectations for outcome,
with all patients expecting improvement or, at worse, no
change. We found that the associations between severity
and expectations were strongest and most reliable for
the motor and non-motor symptom domains, and less
robust for the cognitive and psychological problems and
weakest for the social and ADL domain (See Figure 1A-D).
This may reflect the patient’s model of their disease and
the degree to which they linked different problems to the
underlying PD, and therefore amenability to treatment. For
Table 3 Correlations coefficients * between clinical
variables and PRO-APD severity and expectation domain









Motor severity 0.40 0.49a 0.31 0.15
Motor expectations 0.37 0.46a 0.24 0.36
NMS severity 0.15 0.40 0.27 0.17
NMS expectations 0.02 0.36 0.18 0.35
Cognition/Psychological
severity
0.15 0.62b 0.57b 0.16
Cognition/Psychological
expectations
0.14 0.61b 0.58b 0.45a
Social severity 0.26 0.59b 0.32 0.20
Social expectations 0.00 0.23 0.25 0.30
Total severity 0.31 0.70c 0.43 0.27
Total expectations 0.20 0.49a 0.34 0.45a
*Spearman rank correlation coefficient. UPDRS-3 = Revised Unified Parkinson’s
Disease Rating Scale (Part 3); NMSS = Non Motor Symptom Scale; HADS = Hospital
Anxiety and Depression Scale; ACE-R = Addenbrooke’s Cognitive
Examination (Revised).
ap < 0.05; bp < 0.01; cp < 0.001. Unmarked ≥0.05. The values in bold are the
ones with significant p values.
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memory problems to his/her age may have different
expectations from a treatment targeting PD compared
with a patient who sees the memory problems as an inte-
gral feature of the disease. Helping patients to understand
the nature and extent of the full range of problems as-
sociated with their PD, and the potential impact of
therapy, is likely to be important in helping them make
informed choices and assess the possible impact of any
future treatment.
Low mood might conceivably have had an impact on
expectations, with depressed and anxious patients expect-
ing a less favorable outcome. In practice, depression and
anxiety as measured by the HADS was associated positively
with degree of expected change, although the effect was sig-
nificant only for the cognitive and psychological problems.
Clinical outcomes from advanced treatments such as
DBS, Apo and IJL can produce dramatic improvements
in some patients and for some symptoms, both motor
and non motor. However, not all patients show a marked
improvement and not all symptoms show similar respon-
siveness. An assumption that the most severe (and per-
sonally significant) problems are going to improve, and
by the largest extent, raises the risk that patients may be
dissatisfied with the outcome [18,26]. Identifying such
misperceptions in advance offers the opportunity to
provide the patient with the facts to inform and possibly
adjust their expectations of treatment ahead of time. Al-
though lack of accurate information may contribute to
unrealistic expectations, individual characteristics (such
as optimism) may also play an important role. Optimismis recognized as a dispositional trait that is largely in-
dependent of factors such as mood [27]. Evidence from
patients with other physical conditions suggest that low
levels of optimism is associated with poor outcome,
perhaps because patients fail to engage with treatment or
to be proactive in coping with the challenges of their con-
dition. However, high levels of optimism may also be un-
helpful if they set up expectation that cannot be met or
encourage a passive ‘everything will be alright’ attitude.
Practically, moderate (rather than excessively high or low)
levels of optimism may be the best for outcome in chronic
disease such as multiple sclerosis and Parkinson’s disease
[28] and something that clinicians can encourage when
discussing potential treatments.
The two cases described in this study were chosen to
illustrate somewhat polarized expectations with case X
having extreme levels of positive expectation for the large
majority of problems experienced (which may not have
been achievable), while case Y had lower expectations for
some and no positive expectations for other problems. Both
patients might benefit from a detailed discussion about
what the planned treatment can and cannot reasonably
offer. Patient Y was more depressed and had a significant
degree of cognitive impairment that may have biased their
judgment. However, a more pessimistic and limited set of
expectations is not necessarily bad and may even be closer
to the likely clinical reality. A danger of low expectation is
when they cause a patient to decline available treatment
options.
We note several important limitations to our study. Our
study is a small pilot and further research is required to
demonstrate the scale validity and utility. We appreciate
the current lack of accepted consistency in meaning of the
term “holistic”, and of uniform guidelines on the specific
selection of one treatment modality over another, although
some guidance exists, e.g. significant cognitive impairment
may exclude DBS, but not always exclude IJL or Apo [4].
None-the-less, this is a pragmatic first step which exempli-
fies the benefits of a PRO approach, and which if developed
further could help guide individual patients to be offered
and accept individual therapies.
In conclusion, a PRO approach encompasses a patient-
driven view of care. We present a pilot study using PRO-
APD as a demonstration to provide a simple and pragmatic
assessment of the severity and expectation of treatment,
and which is in line with increased patient participation in
their management. Patients opting for invasive therapy for
PD have moderately high multi-domain symptom load,
and also expect substantial improvements in multiple
domains. These need to be considered when assessing
patients for therapy, so that individual expectations can be
realistic, since unexplored expectations are more likely to
lead to overall dissatisfaction following therapy. Our find-
ings are preliminary. Further validation could lead to the
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1. Tremor. Has tremor/shaking affected any part of your
body?
2. Stiffness or slowness moving. Have you found it
difficult to move or carry out everyday activities because
of stiffness in your muscles or slowness moving?
3. Off Periods. Times when your medication does not
seem to work properly of where the effects wear off
before the next tablet is due. Do you have times when
you remain slow, stiff or shaking even if you have taken
your medication?
4. Dyskinesia. Jerky movements in any part of your body
that you cannot stop? I don’t mean tremor. Have you had
times when a part of your body has been moving more
than usual without you trying to move it?
5. Freezing. Times when you suddenly freeze and cannot
move? Have you felt as if your feet are stuck to the floor?
6. Dystonia. Have you had problems with muscle
spasms, abnormal or distorted posturing or painful spasms
of muscles?
7. Speech. Have you had problems with your speech,
with difficulty in speaking loudly or clearly? Have people
had difficulty understanding you when you talk?
8. Balance / Falls. Have you fallen or felt off balance
and thought you might fall? Have you felt unsteady when
turning around or when leaning over?
NMS domain
9. Swallowing. Have you had problems swallowing
liquids or solids? Have you found yourself dribbling while
drinking or choking while eating?
10. Sleep. Do you have problems with sleep, like falling
asleep at night or staying asleep? Is your sleep disturbed,
for example by unpleasant dreams?
11. Bowels. Do you have problems with your bowels
like constipation, loose stools? Do you need laxatives?
12. Bladder. Do you have problems like urgency, incon-
tinence or need to go to the toilet too frequently at night?
Do you have difficulty holding urine?
13. Pain. Do you suffer from any unexplained pain
other than conditions like arthritis or muscular injury?
Do you have pain or other unpleasant feeling in any part
of your body?
14. Fatigue. Have you experienced extreme tiredness
or lack of energy during the day? I don’t just mean feeling
sleepy. Do you feel fatigued even though you have not
been active?
15. Sexual function. Have you had loss of interest in
sex? Have you had difficulty with sex if you have tried?Have you been unable to have sex compared to how you
would like?
Cognition and psychological domain
16. Concentration. Do you have problems concentrating,
for example during a conversation or while reading a book
or newspaper? Do you find it difficult if you are given too
much information at once?
17. Memory. Do you have problems remembering things?
Do you forget where you have left things or forget things
that you meant to do? Do other people have to remind
you?
18. Impulsive behaviour. Do you do any of the following:
do you gamble more than you can afford (wait for reply).
Do you spend a lot of money shopping? Are you extremely
interested in sex? Do you find it hard to throw things away?
19. Hallucinations/Psychosis. Have you heard or seen
or smelled anything that you knew was not really there,
or other people have told you were not there? Have your
senses played tricks on you?
20. Mood. Do you feel low in mood, sad, hopeless or
unable to enjoy things? Have you felt blue or ‘empty’
21. Anxiety. Have you been troubled by worries that you
cannot get rid of? Have you felt frightened or panicky?
Have you felt tense and nervous?
22. Apathy. Do you have difficulty motivating yourself
to do the things you need to do? Do you need prompting
and encouragement? Do you spend much time sitting
doing nothing?
Social and ADL domain
23. Self-care. Do you have difficulty managing your
day-to-day activities for caring after yourself? Do you have
problems washing, dressing and eating your food?
24. Work. Do you still work? If so, do you have
difficulty doing your job because of your Parkinson’s
disease?
25. Leisure/Hobbies. Do you have difficulty with any
of your leisure activities or hobbies? Have you recently
had to stop doing things that you enjoy?
Socialising. Do you find it difficult to socialize, either
in your home or outside? Do you find social situations
difficult?
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